[11C]SMe-ADAM, an imaging agent for the brain serotonin transporter: synthesis, pharmacological characterization and microPET studies in rats.

N,N-Dimethyl-2-(2-amino-4-methylthiophenylthio)benzylamine (SMe-ADAM, 1) is a highly potent and selective inhibitor of the serotonin transporter (SERT). This compound was labeled with carbon-11 by methylation of the S-desmethyl precursor 10 with [(11)C]methyl iodide to obtain the potential positron emission tomography (PET) radioligand [(11)C]SMe-ADAM. The radiochemical yield was 27 +/- 5%, and the specific radioactivity was 26-40 GBq/micromol at the end of synthesis. Ex vivo and in vivo biodistribution experiments in rats demonstrated a rapid accumulation of the radiotracer in brain regions known to be rich in SERT, such as the thalamus/hypothalamus region (3.59 +/- 0.41%ID/g at 5 min after injection). The specific uptake reached a thalamus to cerebellum ratio of 6.74 +/- 0.95 at 60 min postinjection. The [(11)C]SMe-ADAM uptake in the thalamus was significantly decreased by pretreatment with fluoxetine to 38 +/- 11% of the control value. Furthermore, no metabolites of [(11)C]SMe-ADAM could be detected in the SERT-rich regions of the rat brain. It is concluded that [(11)C]SMe-ADAM may be a suitable PET ligand for SERT imaging in the living brain.

[1]  U. Scheffel,et al.  In Vivo Labeling of Serotonin Uptake Sites with [3H]Paroxetine , 1989, Journal of neurochemistry.

[2]  J. Marcusson,et al.  High affinity [3H]paroxetine binding to serotonin uptake sites in human brain tissue , 1989, Brain Research.

[3]  P Cumming,et al.  Quantitative radioluminography of serotonin uptake sites in the porcine brain , 2001, Synapse.

[4]  H. Happe,et al.  Localization and quantification of the dopamine transporter: comparison of [3H]WIN 35,428 and [125I]RTI-55 , 1995, Brain Research.

[5]  H. T. Chen,et al.  Quantitative autoradiography of 3H-paroxetine binding sites in rat brain. , 1992, Journal of pharmacological and toxicological methods.

[6]  Clinton D Kilts,et al.  Synthesis and characterization of EADAM: a selective radioligand for mapping the brain serotonin transporters by positron emission tomography. , 2005, Nuclear medicine and biology.

[7]  J. Steinbach,et al.  Synthesis of S-([18F]fluoromethyl)-(+)-McN5652 as a potential PET radioligand for the serotonin transporter. , 2001, Nuclear medicine and biology.

[8]  C. Crouzel,et al.  Recommendations for a practical production of [11C]methyl iodide☆ , 1987 .

[9]  Zsolt Szabo,et al.  Positron emission tomography imaging of serotonin transporters in the human brain using [11C](+)McN5652 , 1995, Synapse.

[10]  Alan A. Wilson,et al.  Comparative Evaluation in Nonhuman Primates of Five PET Radiotracers for Imaging the Serotonin Transporters: [11C]McN 5652, [11C]ADAM, [11C]DASB, [11C]DAPA, and [11C]AFM , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[11]  G. Battaglia,et al.  Prenatal exposure to fluoxetine (Prozac) produces site-specific and age-dependent alterations in brain serotonin transporters in rat progeny: evidence from autoradiographic studies. , 1998, The Journal of pharmacology and experimental therapeutics.

[12]  W. Katon,et al.  Increased medical costs of a population-based sample of depressed elderly patients. , 2003, Archives of general psychiatry.

[13]  Sylvain Houle,et al.  In vitro and in vivo characterisation of [11C]-DASB: a probe for in vivo measurements of the serotonin transporter by positron emission tomography. , 2002, Nuclear medicine and biology.

[14]  Ralph Buchert,et al.  Long-term effects of "ecstasy" use on serotonin transporters of the brain investigated by PET. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  Ralph Buchert,et al.  A voxel-based PET investigation of the long-term effects of "Ecstasy" consumption on brain serotonin transporters. , 2004, The American journal of psychiatry.

[16]  Marc Laruelle,et al.  Regional and subcellular localization in human brain of [3H]paroxetine binding, a marker of serotonin uptake sites , 1988, Biological Psychiatry.

[17]  S. Houle,et al.  Novel Radiotracers for Imaging the Serotonin Transporter by Positron Emission Tomography: Synthesis, Radiosynthesis, and in Vitro and ex Vivo Evaluation of (11)C-Labeled 2-(Phenylthio)araalkylamines. , 2000, Journal of medicinal chemistry.

[18]  B. Fanburg,et al.  Serotonin uptake by bovine pulmonary artery endothelial cells in culture. I. Characterization. , 1986, The American journal of physiology.

[19]  P. Brust,et al.  Radioligands for the study of the 5-HT transporter in vivo. , 1999, IDrugs : the investigational drugs journal.

[20]  H N Wagner,et al.  [11C](+)McN5652 as a radiotracer for imaging serotonin uptake sites with PET. , 1993, Life sciences.

[21]  M. Zienowicz,et al.  Pentylenetetrazol-kindling of seizures selectively decreases [3H]-citalopram binding in the CA-3 area of rat hippocampus , 2002, Neuroscience Letters.

[22]  A. Heinz,et al.  DASB –in vitro binding characteristics on human recombinant monoamine transporters with regard to its potential as positron emission tomography (PET) tracer , 2004, Journal of neurochemistry.

[23]  Zsolt Szabo,et al.  Positron emission tomography imaging of the serotonin transporter in subjects with a history of alcoholism , 2004, Biological Psychiatry.

[24]  H N Wagner,et al.  Positron Emission Tomography of 5-HT Transporter Sites in the Baboon Brain with [11C]McN5652 , 1995, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[25]  Yiyun Huang,et al.  The new PET imaging agent [11C]AFE is a selective serotonin transporter ligand with fast brain uptake kinetics. , 2004, Nuclear medicine and biology.

[26]  Marc Laruelle,et al.  A new positron emission tomography imaging agent for the serotonin transporter: synthesis, pharmacological characterization, and kinetic analysis of [11C]2-[2-(dimethylaminomethyl)phenylthio]-5-fluoromethylphenylamine ([11C]AFM). , 2004, Nuclear medicine and biology.

[27]  R. Wightman,et al.  Release and Uptake Rates of 5‐Hydroxytryptamine in the Dorsal Raphe and Substantia Nigra Reticulata of the Rat Brain , 1998, Journal of neurochemistry.

[28]  Y. Sudo,et al.  Lung as reservoir for antidepressants in pharmacokinetic drug interactions , 1998, The Lancet.

[29]  F. Yasuno,et al.  Serotonin transporter binding in patients with mood disorders: a PET study with [11C](+)McN5652 , 2002, Biological Psychiatry.

[30]  H. Takanaga,et al.  Localization of norepinephrine and serotonin transporter in mouse brain capillary endothelial cells , 2002, Neuroscience Research.

[31]  J. Steinbach,et al.  Positron emission tomography imaging of the serotonin transporter in the pig brain using [11C](+)‐McN5652 and S‐([18F]fluoromethyl)‐(+)‐McN5652 , 2003, Synapse.

[32]  Yiyun Huang,et al.  A PET imaging agent with fast kinetics: synthesis and in vivo evaluation of the serotonin transporter ligand [11C]2-[2-dimethylaminomethylphenylthio)]-5-fluorophenylamine ([11C]AFA). , 2004, Nuclear medicine and biology.

[33]  Joel S Karp,et al.  N,N-dimethyl-2-(2-amino-4-(18)F-fluorophenylthio)-benzylamine (4-(18)F-ADAM): an improved PET radioligand for serotonin transporters. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[34]  S. Ueno.  Genetic polymorphisms of serotonin and dopamine transporters in mental disorders. , 2003, The journal of medical investigation : JMI.

[35]  M. Kraut,et al.  Kinetic Analysis of [11C]McN5652: A Serotonin Transporter Radioligand , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[36]  H. Schindlbauer.  Reaktionen mit Dimethylformamid, 1. Mitt.: Synthese von Carbonsäuredimethylamiden , 1968 .

[37]  David Healy,et al.  The Antidepressant Era , 1998 .

[38]  P. Acton,et al.  Selective in vitro and in vivo binding of [125I]ADAM to serotonin transporters in rat brain , 2000, Synapse.

[39]  Mark Slifstein,et al.  Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography. , 2003, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[40]  Denis Guilloteau,et al.  Carbon-11 labelling of MADAM in two different positions: a highly selective PET radioligand for the serotonin transporter , 2001 .

[41]  R. Rhoades,et al.  Thalamocortical afferents in rat transiently express high-affinity serotonin uptake sites , 1996, Brain Research.

[42]  J. Greenberg,et al.  Synthesis and evaluation of N,N-dimethyl-2-(2-amino-5-[18F]fluorophenylthio)benzylamine (5-[18F]-ADAM) as a serotonin transporter imaging agent. , 2004, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[43]  J. Steinbach,et al.  S‐[18F]fluoromethyl‐(+)‐McN5652, a PET tracer for the serotonin transporter: Evaluation in rats , 2003, Synapse.

[44]  O Sabri,et al.  In vivo Measurement of the Serotonin Transporter with (S)-([18F]fluoromethyl)-(+)-McN5652 , 2003, Neuropsychopharmacology.

[45]  John Hilton,et al.  Positron emission tomography of striatal serotonin transporters in Parkinson disease. , 2003, Archives of neurology.

[46]  U. Müller,et al.  Neuroimaging of the Serotonin Transporter: Possibilities and Pitfalls. , 2006 .

[47]  J. Votaw,et al.  Synthesis, radiosynthesis, and biological evaluation of carbon-11 and iodine-123 labeled 2beta-carbomethoxy-3beta-[4'-((Z)-2-haloethenyl)phenyl]tropanes: candidate radioligands for in vivo imaging of the serotonin transporter. , 2004, Journal of Medicinal Chemistry.

[48]  P. Brust,et al.  Functional Expression of the Serotonin Transporter in Immortalized Rat Brain Microvessel Endothelial Cells , 2000, Journal of neurochemistry.

[49]  H. Kung,et al.  New PET imaging agent for the serotonin transporter: [(18)F]ACF (2-[(2-amino-4-chloro-5-fluorophenyl)thio]-N,N-dimethyl-benzenmethanamine). , 2002, Journal of medicinal chemistry.

[50]  Denis Guilloteau,et al.  Pharmacological Characterization ofN,N-Dimethyl-2-(2-amino-4-methylphenyl thio)benzylamine as a Ligand of the Serotonin Transporter with High Affinity and Selectivity , 2003, Journal of Pharmacology and Experimental Therapeutics.